Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration... (statement relating to these securities h...)

Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement

Date:6/3/2008

statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

In addition, the Company also announced that it has filed two registration statements on Form S-8 to register: (i) shares of restricted common stock and shares of common stock underlying stock options issued under its 2006 Stock Incentive Plan, and (ii) shares of common stock underlying certain stock options granted by the Company prior to its initial public offering. The Company has been advised by the holders of the shares being registered in the Form S-8 registration statements that they have no present intent to sell any of such shares.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
3. Experiments reveal unexpected activity of fuel cell catalysts
4. Using catalysts to stamp nanopatterns without ink
5. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
6. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
7. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
8. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
9. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
10. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
11. Sonus Pharmaceuticals and OncoGenex Technologies to Merge

Post Your Comments:

Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration...(statement relating to these securities h...)